GlaxoSmithKline Stock – GlaxoSmithKline’s (GSK) “Sell” Rating Reiterated at Deutsche Bank Aktiengesellschaft
GSK has been the topic of several other research reports. UBS Group reissued a “neutral” rating on shares of GlaxoSmithKline in a research note on Tuesday, May 11th. SVB Leerink restated a “market perform” rating on shares of GlaxoSmithKline in a report on Monday, March 29th. Berenberg Bank restated a “buy” rating on shares of GlaxoSmithKline in a report on Thursday, February 11th. Zacks Investment Research upgraded shares of GlaxoSmithKline from a “strong sell” rating to a “hold” rating and set a $40.00 target price on the stock in a report on Tuesday, April 20th. Finally, Morgan Stanley restated an “equal weight” rating on shares of GlaxoSmithKline in a report on Tuesday, April 20th. Three investment analysts have rated the stock with a sell rating, five have issued a hold rating and seven have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $40.00.
GlaxoSmithKline stock traded down $0.14 during midday trading on Friday, hitting $40.09. 111,380 shares of the stock were exchanged, compared to its average volume of 5,403,438. The firm has a fifty day moving average price of $38.01. GlaxoSmithKline has a 52 week low of $33.26 and a 52 week high of $42.40. The stock has a market capitalization of $107.95 billion, a PE ratio of 14.68, a PEG ratio of 4.03 and a beta of 0.70. The company has a debt-to-equity ratio of 1.10, a current ratio of 0.91 and a quick ratio of 0.61.
GlaxoSmithKline (NYSE:GSK) last released its quarterly earnings data on Wednesday, April 28th. The pharmaceutical company reported $0.63 earnings per share for the quarter, hitting the consensus estimate of $0.63. GlaxoSmithKline had a net margin of 16.01% and a return on equity of 24.57%. The business had revenue of $10.23 billion for the quarter, compared to analyst estimates of $10.66 billion. On average, research analysts forecast that GlaxoSmithKline will post 2.74 EPS for the current fiscal year.
In other news, major shareholder Plc Glaxosmithkline sold 32,005,260 shares of GlaxoSmithKline stock in a transaction that occurred on Thursday, May 20th. The shares were sold at an average price of $12.25, for a total value of $392,064,435.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 10.00% of the stock is owned by company insiders.
Several large investors have recently added to or reduced their stakes in the stock. Arkadios Wealth Advisors grew its stake in shares of GlaxoSmithKline by 8.9% in the first quarter. Arkadios Wealth Advisors now owns 3,255 shares of the pharmaceutical company’s stock valued at $116,000 after buying an additional 267 shares in the last quarter. FineMark National Bank & Trust grew its stake in shares of GlaxoSmithKline by 2.8% in the first quarter. FineMark National Bank & Trust now owns 9,892 shares of the pharmaceutical company’s stock valued at $353,000 after buying an additional 270 shares in the last quarter. SevenBridge Financial Group LLC grew its stake in shares of GlaxoSmithKline by 4.0% in the first quarter. SevenBridge Financial Group LLC now owns 7,014 shares of the pharmaceutical company’s stock valued at $250,000 after buying an additional 272 shares in the last quarter. Clearstead Advisors LLC grew its stake in shares of GlaxoSmithKline by 11.4% in the first quarter. Clearstead Advisors LLC now owns 2,682 shares of the pharmaceutical company’s stock valued at $96,000 after buying an additional 275 shares in the last quarter. Finally, Kavar Capital Partners Group LLC grew its stake in shares of GlaxoSmithKline by 0.5% in the first quarter. Kavar Capital Partners Group LLC now owns 60,988 shares of the pharmaceutical company’s stock valued at $2,177,000 after buying an additional 295 shares in the last quarter. 12.10% of the stock is owned by institutional investors and hedge funds.
GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
Featured Story: How can investors find ex-dividend dates?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Featured Article: Cash Flow Analysis in Stock Selection
7 Outdoor Recreation Stocks For Growth And Dividends
If American’s liked outdoor activities before, they love them even more now. The COVID-19 pandemic has done many things, and one of them is reinvigorating American’s love of the outdoors. Data from across the industry shows a sustained uptick in revenue that has the entire complex moving higher.
The RV Industry Association, for example, reports shipments of RVs are up greater than 30% in 2020 and are expected to grow another 20% or more in 2021. If data from the two of the industry’s largest manufacturers are any indication, that forecast is very conservative.
And the gains aren’t limited to RVs. Everything that has anything to do with outdoor recreation is booming. Sales at Dicks Sporting Goods, an iconic brand for retail and the outdoors, has seen a sustained 20% increase in revenue since the 2nd quarter shutdowns. If anything, revenue in this sector is being held back by rapidly declining inventory and tight shipping conditions.
The stocks we are about to show all have something in common; the outdoors. Within the group, you will find everything from RVs to Radios and everything in between an outdoor enthusiast could need or want. Some pay dividends and some don’t, but all will deliver solid returns to investors in 2021.
View the “7 Outdoor Recreation Stocks For Growth And Dividends”.